Name: Tivozanib: Adverse Event Profile and How Toxicities are Managed
Uploaded: 2022-06-22T13:00:00.000Z
Description: Dr Thomas Hutson reviews the adverse event profile of tivozanib and provides advice to community oncologists on how to best manage these toxicities.

Waldenström Macroglobulinemia

Blood Cancers

Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Childhood Cancers

Anal Cancer

Colorectal Cancer

Esophageal Cancer

Gallbladder Cancer

Gastrointestinal stromal tumor

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancers

Bladder Cancer

Kidney Cancer

Prostate Cancer

Testicular Cancer

Genitourinary Cancers

Cervical Cancer

Ovarian Cancer

Uterine Cancer

Vulvar Cancer

Gynecologic Cancer

Head & Neck Cancer

Immunotherapy

Acute Myeloid Leukemia

Leukemia

Mesothelioma

Lung Cancer

Follicular Lymphoma

Mantle Cell Lymphoma

Non-Hodgkin Lymphoma

Small Lymphocytic Lymphoma (SLL)

Lymphoma

Myeloma

Cancer of Unknown Primary

Carcinoid Cancer

Neuroendocrine Cancer

Rare Cancers

Sarcoma

Melanoma

Skin Cancer

Thyroid Cancer

News

Cancer Horizons

All News

Blogs

Caregiving

Diet and Exercise

Financial

Psychosocial

Recipes

Sexual Health

Side Effect

Survivorship

Videos

All Videos

CURE Connections

CURE Expert Connections®

CURE Speaking Out

CURE TV

Educated Patient Sound Bites

On Demand: Webinars

Conferences

Conference Coverage 

Conference Listing 

Events

CURE Adventures

CURE Awards

Educated Patient In Person Education

Educated Patient Virtual Education

Resources

Advocacy Groups

Art Gallery

Clinical Trial Corner

Partners

Podcasts

Publications

Share Your Story

Subscribe

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

About

Advertise / Support

Contact

CancerNetwork.com

TargetedOnc.com

OncLive.com

OncNursingNews.com

Terms & Conditions

Privacy

Do Not Sell My Information

CURE - Oncology & Cancer News for Patients & Caregivers

Twitter

Facebook

Youtube

Instagram

Spotlight

Breast Cancer Webinar Series

Cancer Type

Bladder

Breast

Kidney

Lung

Ovarian

Prostate

Skin

About CURE

Press Releases

Write for CURE

1rem

View

Role of Tivozanib in Renal Cell Carcinoma (RCC)

CURE Expert Connections

Thomas Hutson, DO, PharmD discusses the role of tivozanib in the treatment landscape for patients with renal cell carcinoma.

An overview of the treatment options available for patients with renal cell carcinoma (RCC).

Treatment Options for Patients with Renal Cell Carcinoma (RCC)

Dr Thomas Hutson reviews the TIVO-3 trial, including the most recent data that was presented at ASCO GU.

Clinical Implications of the TIVO-3 Trial

Dr Thomas Hutson reviews the adverse event profile of tivozanib and provides advice to community oncologists on how to best manage these toxicities.

Tivozanib: Adverse Event Profile and How Toxicities are Managed

Dr Thomas Hutson shares his experience with tivozanib in his practice and ways to counsel patients regarding treatment options in the third-line setting.

Experience with Tivozanib in the 3rd Line Setting for Patients with RCC

Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.

Future Perspectives in Renal Cell Carcinoma (RCC)

CURE Expert Connections® is a video series designed to help patients and their loved ones along their cancer care journey by offering information and expert advice from leaders in oncology care. Expert medical professionals share their knowledge and insights on an array of topics to allow for a better understanding of what to expect following a cancer diagnosis. Expert Connections hopes to bridge the gap between patients and oncology professionals to ensure no question is left unanswered.

Tivozanib: Adverse Event Profile and How Toxicities are Managed

EP: 1.Treatment Options for Patients with Renal Cell Carcinoma (RCC)

EP: 2.Clinical Implications of the TIVO-3 Trial

EP: 3.Tivozanib: Adverse Event Profile and How Toxicities are Managed

EP: 4.Experience with Tivozanib in the 3rd Line Setting for Patients with RCC

EP: 5.Future Perspectives in Renal Cell Carcinoma (RCC)